Targeting a Rare Blood Cancer
The FDA approved a molecularly targeted therapeutic to treat certain pediatric patients and young adults with anaplastic large-cell lymphoma, a rare form of non-Hodgkin lymphoma.
Progress Against Cancer
The FDA approved a molecularly targeted therapeutic to treat certain pediatric patients and young adults with anaplastic large-cell lymphoma, a rare form of non-Hodgkin lymphoma.
The FDA approved the first once-a-day pill to lower the levels of testosterone in certain patients with prostate cancer. The U.S. Food and Drug Administration (FDA) has approved the first oral gonadotropin-releasing hormone (GnRH)...
The FDA approved the molecularly targeted therapeutic selinexor to be used in combination with another targeted agent and a synthetic corticosteroid to treat certain patients with multiple myeloma. The U.S. Food and Drug Administration...
The U.S. FDA has approved a new targeted therapy for certain patients with HER2-positive breast cancer who were previously treated with other targeted therapies.
The FDA has expanded the approval of a molecularly targeted therapeutic to treat certain pediatric and adult patients with medullary thyroid cancer. The U.S. Food and Drug Administration has approved pralsetinib (Gavreto) to treat certain adult and pediatric patients age...
Roughly 6 percent of men and women in the United States will be diagnosed with lung and bronchus cancer during their lifetime. While both the incidence and mortality rates have been steadily decreasing in...
The FDA approved the use of an immunotherapeutic in combination with chemotherapy to treat certain patients with triple-negative breast cancer.
The FDA granted approval to expand the use of a minimally invasive biomarker test to identify certain patients with ovarian, lung, breast, or prostate cancer eligible for treatment with specific molecularly targeted therapeutics.
The FDA approved a combination of two immune checkpoint inhibitors to treat adult patients with unresectable malignant pleural mesothelioma.
The FDA approved the first liquid biopsy companion diagnostic that uses next-generation sequencing to test for EGFR gene mutations in certain types of lung cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More